Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.
暂无分享,去创建一个
Mark Clemons | Ian F Tannock | Andreas Laupacis | A. Laupacis | I. Tannock | G. Tomlinson | G. Dranitsaris | M. Clemons | E. Amir | O. Freedman | N. Miller | George Dranitsaris | Naomi Miller | C. Simmons | Christine Simmons | Eitan Amir | Orit Freedman | William Geddie | Farrah Kassam | Maria Oldfield | George Tomlinson | W. Geddie | M. Oldfield | F. Kassam
[1] M. Brennan,et al. The variability of estrogen receptors in metastatic breast cancer. , 1979, American journal of surgery.
[2] M. Clemons,et al. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? , 2009, The Lancet. Oncology.
[3] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[4] G. Bussolati,et al. Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.
[5] A. Thompson,et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.
[6] I. Holdaway,et al. Variation in receptor status between primary and metastatic breast cancer , 1983, Cancer.
[7] A. Chandra,et al. BSCC Code of Practice – fine needle aspiration cytology , 2009, Cytopathology : official journal of the British Society for Clinical Cytology.
[8] M. Gail,et al. Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.
[9] L. Pusztai,et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. , 2010, The oncologist.
[10] M. Clemons,et al. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).
[11] F. Orsi,et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] I. Ellis,et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast , 2006, Journal of Clinical Pathology.
[13] Edith A Perez,et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Dranitsaris,et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] P. Regitnig,et al. Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas , 2004, The Journal of pathology.
[16] W. Woodward,et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Pieter Wesseling,et al. Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.
[18] N. Sneige,et al. Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys to Increasing Testing Accuracy , 2005, Advances in anatomic pathology.
[19] M. Buchanan,et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Peter A Kaufman,et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Marc Ladanyi,et al. Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases , 2008, Clinical Cancer Research.
[22] J. Bergh,et al. Discordance in hormone receptor status in breast cancer during tumor progression. , 2010 .
[23] J. Bergh,et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression , 2010, Breast Cancer Research and Treatment.
[24] Benjamin D. L. Li,et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer , 1994, Journal of surgical oncology.
[25] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[26] E. Brogi,et al. The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury? , 2011, Current oncology reports.